In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Vivo's Deals Of The Month, September 2016

Executive Summary

In Vivo's editors pick September's most significant deals, including another big pharma JV for Verily and an AD IPO. (Article free with registration.)

Top Alliance: Sanofi And Verily's Diabetes JV

Sanofi and Verily Life Sciences will invest $500 million in their new joint venture Onduo, which will develop integrated treatment and monitoring solutions for diabetes. [See Deal] Onduo will operate independently from its creators, but can draw on their resources as well as those from outside partners. With the first product expected on the market within two to three years, Onduo CEO Joshua Riff, MD, envisions using Sanofi's drug expertise and Verily's knowledge of miniature electronics, analytics and consumer software development to create delivery and monitoring technologies that give type 2 (and eventually type 1) patients the ability to better manage their disease. The joint venture is the second in as many months for Verily, whose Galvani Bioelectronics neuromodulation JV with GlaxoSmithKline PLC was our pick for top alliance in August. [See Deal]

Top Financing: AC Immune's IPO

Swiss Alzheimer's drug and vaccine developer AC Immune SA netted $61.4 million in a Nasdaq initial public offering of 6 million shares (upsized from the 4.5 million it had originally planned) at $11, the low end of its anticipated $11–$13 range). [See Deal]The company will use the proceeds to further develop its therapeutic and diagnostic neurodegenerative disease pipeline. Its most advanced candidate is crenezumab (an anti-abeta antibody) in Phase II/III for Alzheimer's disease prevention and treatment, partnered with Roche/Genentech Inc. Under an alliance signed with Biogen Inc. in April 2016, AC Immune is also developing brain-imaging biomarkers for two protein targets – alpha-synuclein and TDP43, both implicated in neurodegenerative diseases, including Parkinson's. Since its 2003 inception, AC Immune has raised $127.5 million, most recently a $43.5 million Series E round in May 2016.

Top M&A: Allergan's Buying Spree

Allergan PLC built a non-alcoholic steatohepatitis franchise overnight in mid-September, acquiring Tobira Therapeutics Inc. for $1.7 billion on September 20 and announcing a $50 million buy-out of Akarna Therapeutics Inc. the same day. [See Deal][See Deal]Tobira's Phase II NASH candidate cenicriviroc is a dual CCR2/CCR5 inhibitor that the company thinks could succeed as a NASH therapeutic by addressing both the fibrotic and inflammatory components of the disease. Akarna has a preclinical farnesoid X receptor antagonist for NASH. That's not all, folks: Allergan rounded out the month by paying $60 million up front for gene therapy developer RetroSense Therapeutics LLC and $639 million for computational dermatology drug designer Vitae Pharmaceuticals Inc.[See Deal][See Deal]

Advertisement

Related Content

Immunotherapies Set To Spark Alzheimer's Drug Market
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Sanofi, Google’s Verily Enter Diabetes JV To Produce Joined Up Solutions
Allergan’s RetroSense Buy Marks Move Into Gene Therapy
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel